NCAM1 and Cognitive impairment: This model is supported by our findings that exogenous application of bacterially produced PSA rescued LTP deficits in PCE offspring, suggesting that PSA-NCAM represents a potential therapeutic target for the treatment of synaptic and cognitive deficits associated with PCE.